Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04365101 · ClinicalTrials.gov registry record · Phase 1
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
A Phase 1 study, sponsored by Celularity Incorporated.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04365101: Clinical Trial Phase 1 study, sponsored by Celularity Incorporated.
NCT04365101 is a Phase 1 study that was terminated before completion, run by Celularity Incorporated. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04365101, a Phase 1 study, was terminated before completion, sponsored by Celularity Incorporated.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.
Primary Outcome
Number and severity of treatment-emergent adverse events (TEAEs), assessed according to CTCAE version 5.0. TEAEs were defined as adverse events that started or worsened on or after the first dose of study treatment.
Interventions
- BIOLOGICAL CYNK-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2023-02-15 |
| Phase | Phase 1 |
Why NCT04365101 stopped before completion
NCT04365101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which CYNK-001 is the first listed.
NCT04365101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04365101 about?
NCT04365101 is a clinical study titled "Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19". This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.
What is the current status of trial NCT04365101?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2020-09-02. Estimated completion is 2023-02-15.
What interventions are being tested in trial NCT04365101?
The interventions under investigation include: CYNK-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04365101?
This trial is sponsored by Celularity Incorporated, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04365101's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI